ライフサイエンスコーパス: alefacept

1 belatacept and sirolimus; six also received alefacept.

2 observed, particularly with the addition of alefacept.

3 patients treated with the CD2-targeted agent alefacept.

4 with chronic psoriasis received intravenous alefacept (0.025, 0.075, or 0.150 mg per kilogram of bod

5 Alefacept (15 mg) or placebo was administered intramuscu

6 These data establish that alefacept activates gene expression programs in leukocyt

7 Thus alefacept acts as an effector molecule, mediating cognat

8 In conclusion, alefacept administration after depletion and with tacrol

9 fter treatment, 28 patients who had received alefacept alone were clear or almost clear of psoriasis.

10 Alefacept, an immunomodulatory recombinant fusion protei

11 bility, 33 were randomly assigned to receive alefacept and 16 to receive placebo.

12 on that influence the biological activity of alefacept and may contribute to its efficacy and patient

13 Safety and tolerability were similar in the alefacept and placebo groups.

14 The results of a trial with a second agent, alefacept are pending public review.

15 This study 1) establishes alefacept as a novel CD2 agonist molecule for induction

16 controlled, double-blind study, we evaluated alefacept as a treatment for psoriasis.

17 The recombinant protein alefacept binds to CD2 on memory effector T lymphocytes,

18 months, or 15 months after the last dose of alefacept, both the 4-hour and the 2-hour C-peptide AUCs

19 Alefacept competitively inhibited cell bilayer adhesion

20 ng human CD2-transgenic mice and isoforms of alefacept confirmed the requirement for Fc gamma R bindi

21 Alefacept could be useful to preserve beta-cell function

22 Tem cells, is targeted by the fusion protein alefacept, depleting Tem cells and central memory T (Tcm

23 Whereas alefacept down-regulated TCRs CD3D and CD2 in responders

24 Experimentation using isoforms of alefacept engineered to have amino acid substitutions in

25 Treatment with alefacept for 12 weeks is associated with improvement in

26 0.015 nmol/L (95% CI -0.080 to 0.110) in the alefacept group and decreased by 0.115 nmol/L (-0.278 to

27 ts were about 50% reduced (P < 0.001) in the alefacept group compared with placebo at 24 months.

28 was significantly lower at 12 months in the alefacept group than in the placebo group.

29 In the alefacept group, 14 (42%) participants had grade 3 or 4

30 In the alefacept group, 29 (88%) participants had an adverse ev

31 two weeks after treatment was greater in the alefacept groups (38, 53, and 53 percent in the groups r

32 However, alefacept improves psoriasis in only approximately 50% o

33 We studied the immunologic effects of alefacept in a group of psoriasis patients during treatm

34 Alefacept in combination with MTX may be an effective an

35 We confirmed the agonistic effects of alefacept in PBMC in vitro, which were similar to CD3/CD

36 ohort 3 recipients (n = 5) were treated with alefacept in place of basiliximab, and more intense LFA-

37 detection of the pharmacological effects of alefacept in vivo.

38 Alefacept is a chimeric protein combining CD58 immunoglo

39 Alefacept is an LFA3-Ig fusion protein that binds to CD2

40 Alefacept is potential future therapeutic for organ tran

41 some animals also received CD2 blockade with alefacept (LFA3-Ig).

42 we show that the CD2-specific fusion protein alefacept (lymphocyte function-associated antigen-3-Ig;

43 Alefacept mediated maximal adhesion of CD2(+) T cells to

44 Alefacept mediated T cell killing by NK cells and adhesi

45 l information is needed to correctly predict Alefacept-mediated bridge formation.

46 A mechanistic model for alefacept-mediated cell-bilayer adhesion allowed fitting

47 Alefacept mediates adhesion by bridging CD2 on T cells t

48 that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells ex

49 Alefacept modulates the function of and selectively indu

50 % in small case series using the CD2-blocker alefacept or TNF-alpha antagonists.

51 for placebo vs 0.36 units per kg per day for alefacept; p=0.02) and the rate of hypoglycaemic events

52 e patients were randomly assigned to receive alefacept plus MTX (n = 123) or placebo plus MTX (n = 62

53 14 was achieved by 53% of patients receiving alefacept plus MTX compared with 17% of those receiving

54 At week 24, 54% of patients in the alefacept plus MTX group achieved an ACR20 response, com

55 In the alefacept plus MTX group, the incidence of serious adver

56 d swollen joint counts in patients receiving alefacept plus MTX were -8.0 and -6.3, respectively.

57 newly diagnosed T1D, two 12-week courses of alefacept preserved C-peptide secretion, reduced insulin

58 e primary outcome was not met, at 12 months, alefacept preserved the 4 h C-peptide AUC, lowered insul

59 The addition of alefacept provided no additional survival benefit, but w

60 rvival in rhesus monkeys, but induction with alefacept provides no survival benefit and increases the

61 Alefacept reduced peripheral-blood memory effector T-lym

62 ion that included tacrolimus with or without alefacept reliably prolonged renal allograft survival in

63 r bivalently and monovalently bound forms of alefacept, respectively.

64 Alefacept selectively targets CD45RO+ memory effector T

65 Specifically evaluated is the ability of alefacept to activate intracellular signals mediated via

66 Furthermore, alefacept-treated animals demonstrated increased alloant

67 Alefacept treatment depleted CD4+ and CD8+ central memor

68 Furthermore, responding patients to alefacept treatment show unique patterns of gene modulat

69 ents were randomly assigned (2:1) to receive alefacept (two 12-week courses of 15 mg intramuscularly

70 blind, placebo-controlled trial, we compared alefacept (two 12-week courses of 15 mg/wk i.m., separat

71 (mean of 10.9 events per person per year for alefacept vs 17.3 events for placebo; p<0.0001) was sign

72 In vitro, alefacept was found to enhance CD4 effector memory T cel

73 Alefacept was well tolerated and nonimmunogenic.

74 We postulated that alefacept would arrest autoimmunity and preserve residua

75 hypothesized that the immunomodulatory drug alefacept would result in targeted quantitative and qual